Lv7
3559 积分 2021-03-16 加入
First-line treatment for advanced NSCLC in older patients and those with poor performance status
6个月前
已完结
Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer
8个月前
已关闭
Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer
8个月前
已完结
Chronic Hepatitis B Infection
9个月前
已完结
Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer
10个月前
已完结
The immune functions of PCSK9: Local and systemic perspectives
1年前
已完结
PCSK9 is a promising prognostic marker in patients with advanced NSCLC
1年前
已完结
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
1年前
已关闭
Initial chemotherapy for locally advanced and metastatic NUT carcinoma
1年前
已关闭
The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer
1年前
已完结
皖公网安备34019202002308
